Evidence map›Paper›PMID 34229889›Full record

ArticleVaccine2022

Tanzania's human papillomavirus (HPV) vaccination program: Community awareness, feasibility, and acceptability of a national HPV vaccination program, 2019.

Anyie J Li, Fatuma Manzi, Furaha Kyesi, Yusuf Makame, William Mwengee, Monica Fleming, Abdallah Mkopi, Selemani Mmbaga, Dafrossa Lyimo, Anagha Loharikar

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Anyie J LiCDC Foundation, Atlanta, GA, USA; Global Immunization Division, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: anyieli@cdc.gov.
Fatuma ManziIfakara Health Institute, Dar es Salaam, Tanzania.
Furaha KyesiMinistry of Health, Community Development, Gender, Elderly, and Children, Dar es Salaam, Tanzania.
Yusuf MakameMinistry of Health Zanzibar, Zanzibar, Tanzania.
William MwengeeWorld Health Organization, Tanzania Country Office, Dar es Salaam, Tanzania.
Monica FlemingGlobal Immunization Division, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abdallah MkopiIfakara Health Institute, Dar es Salaam, Tanzania.
Selemani MmbagaIfakara Health Institute, Dar es Salaam, Tanzania.
Dafrossa LyimoMinistry of Health, Community Development, Gender, Elderly, and Children, Dar es Salaam, Tanzania.
Anagha LoharikarGlobal Immunization Division, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Centers for Disease Control and Prevention · USIfakara Health Institute · TZMinistry of Health, Community Development, Gender, Elderly and Children · TZ

Funding

Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

backgroundIn April 2018, Tanzania introduced the human papillomavirus (HPV) vaccine nationally to 14-year-old girls, utilizing routine delivery strategies (i.e. vaccinating girls at health facilities and community outreach, including schools). We sought to assess awareness, feasibility, and acceptability of the HPV vaccination program among health workers and community-level stakeholders.

methodsWe conducted cross-sectional in-person surveys among health workers, school personnel, community leaders, and council leaders in 18 council areas across six regions of Tanzania in October-November 2019. Regions were purposively selected to provide demographic, geographic, and vaccination coverage variability; sub-regional levels used random or stratified random sampling. Surveys included questions on HPV vaccine training and knowledge, delivery strategy, target population, and vaccine and program acceptability. Descriptive analysis was completed for all variables stratified by respondent groups.

resultsAcross the 18 councils, there were 461 respondents, including health workers (165), school personnel (135), community leaders (143), and council leaders (18). Over half of each respondent group (50-78%) attended a training or orientation on HPV vaccine. Almost 75% of the health workers and school personnel respondent groups, and less than half (45%) of community leaders correctly identified the target age group for HPV vaccine. Most (80%) of the health workers indicated HPV vaccination was available at health facilities and schools; most (79%) indicated that the majority of girls receive HPV vaccine in school. Approximately half (52%) of all respondents reported hearing misinformation about HPV vaccine, but 97% of all respondents indicated that HPV vaccine was either "very accepted" or "somewhat accepted" in their community.

conclusionThe HPV vaccination program in Tanzania was well accepted by community stakeholders in 18 councils; adequate knowledge of HPV vaccine and the HPV vaccination program was demonstrated by health workers and school personnel. However, continued technical support for integration of HPV vaccination as a routine immunization activity and reinforcement of basic knowledge about HPV vaccine in specific community groups is needed. The Tanzania experience provides an example of how this vaccine can be integrated into routine immunization delivery strategies and can be a useful resource for countries planning to introduce HPV vaccine as well as informing global partners on how to best support to countries in operationalizing their HPV vaccine introduction plans.

Indexed as

AlphapapillomavirusPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsAdolescentCross-Sectional StudiesFeasibility StudiesFemaleHealth Knowledge, Attitudes, PracticeHumansImmunization ProgramsPapillomaviridaePatient Acceptance of Health CareTanzaniaVaccinationPapillomavirus VaccinesHuman papillomavirusHuman papillomavirus vaccineTanzania

Identifiers

PMID34229889
PMCPMC9601816
OpenAlexW3177983400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.